PharmaCyte Biotech Inc (PMCB)

[Deborah1]

The Von Hoff Factor

Last May PMCB delivered a major breakthrough. Translational Drug Development of Arizona agreed to conduct preclinical and clinical trials.
The gentleman you see pictured here is the head of Translational Drug- Dr. Daniel Von Hoff. His company has spent the last 2 decades developing cancer drugs. He was on President Bush's National Cancer Society Board, the FDA's oncology Advisory Committee, and is the former President of the American Association for Cancer Research.
Under Von Hoff's direction, the first preliminary studies have been concluded, and the clinical protocol for the Phase 2B trial has been developed. The next step is planning the commencement of the trial with the FDA and other similar agencies Internationally.
On December 22 PMCB announced its Pancreatic Cancer Therapy had received "Orphan Drug Status" from the US FDA- a huge coup. Thanks to the proximity to Christmas, the announcement did not receive proper recognition. To see the evidence on the FDA web site, simply Click Here.
Orphan Drug status is reserved for drugs or treatments for "rare, life threatening diseases." Once approved, PMCB will own the drug exclusively for 7 years.